{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:17:18Z","timestamp":1782436638745,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11102-023-01324-5","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T02:01:40Z","timestamp":1686794500000},"page":"266-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Refractory somatotroph adenomas"],"prefix":"10.1007","volume":"26","author":[{"given":"Monica R.","family":"Gadelha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"1324_CR1","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, Endocrinology E, S.o (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1\u2013G24","journal-title":"Eur J Endocrinol"},{"key":"1324_CR2","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.21037\/gs-20-873","volume":"10","author":"X Liu","year":"2021","unstructured":"Liu X, Dai C, Feng M, Li M, Chen G, Wang R (2021) Diagnosis and treatment of refractory pituitary adenomas: a narrative review. Gland Surg 10:1499\u20131507","journal-title":"Gland Surg"},{"key":"1324_CR3","doi-asserted-by":"publisher","first-page":"20200321","DOI":"10.1259\/bjr.20200321","volume":"93","author":"A Conficoni","year":"2020","unstructured":"Conficoni A, Feraco P, Mazzatenta D, Zoli M, Asioli S, Zenesini C, Fabbri VP, Cellerini M, Bacci A (2020) Biomarkers of pituitary macroadenomas aggressive behaviour: a conventional MRI and DWI 3T study. Br J Radiol 93:20200321","journal-title":"Br J Radiol"},{"key":"1324_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12020-018-1590-8","volume":"60","author":"X Antunes","year":"2018","unstructured":"Antunes X, Ventura N, Camilo GB, Wildemberg LE, Guasti A, Pereira PJM, Camacho AHS, Chimelli L, Niemeyer P, Gadelha MR, Kasuki L (2018) Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine 60:415\u2013422","journal-title":"Endocrine"},{"key":"1324_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","volume":"24","author":"MR Gadelha","year":"2013","unstructured":"Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24:238\u2013246","journal-title":"Trends Endocrinol Metab"},{"key":"1324_CR6","doi-asserted-by":"crossref","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen MC, Melmed S (2020) : Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord 21, 667\u2013678","DOI":"10.1007\/s11154-020-09588-z"},{"key":"1324_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1517\/14656566.2016.1146688","volume":"17","author":"LE Wildemberg","year":"2016","unstructured":"Wildemberg LE, Gadelha MR (2016) Pasireotide for the treatment of acromegaly. Expert Opin Pharmacother 17:579\u2013588","journal-title":"Expert Opin Pharmacother"},{"key":"1324_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. The Lancet Diabetes & Endocrinology 2:875\u2013884","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"1324_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1530\/EJE-18-0616","volume":"179","author":"M Buchfelder","year":"2018","unstructured":"Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ, Ghigo E, Camacho-Hubner C, Pan K, Lavenberg J, Jonsson P, Hey-Hadavi JH (2018) Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol 179:419\u2013427","journal-title":"Eur J Endocrinol"},{"key":"1324_CR10","doi-asserted-by":"crossref","unstructured":"Knappe UJ, Petroff D, Quinkler M, Schmid SM, Schofl C, Schopohl J, Stieg MR, Tonjes A (2020) participants of the German Acromegaly, R.: Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry. Eur J Endocrinol 182, 275\u2013284","DOI":"10.1530\/EJE-19-0784"},{"key":"1324_CR11","doi-asserted-by":"crossref","unstructured":"Singh R, Didwania P, Lehrer EJ, Sheehan D, Sheehan K, Trifiletti DM, Sheehan JP (2020) : Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes. J Neurooncol","DOI":"10.1007\/s11060-020-03552-2"},{"key":"1324_CR12","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1210\/jc.2019-00825","volume":"104","author":"S Chiloiro","year":"2019","unstructured":"Chiloiro S, Bima C, Tartaglione T, Giampietro A, Gessi M, Lauretti L, Anile C, Colosimo C, Rindi G, Pontecorvi A, De Marinis L, Bianchi A (2019) Pasireotide and Pegvisomant Combination Treatment in Acromegaly resistant to second-line therapies: a longitudinal study. J Clin Endocrinol Metab 104:5478\u20135482","journal-title":"J Clin Endocrinol Metab"},{"key":"1324_CR13","doi-asserted-by":"publisher","first-page":"700007","DOI":"10.3389\/fneur.2021.700007","volume":"12","author":"M Luo","year":"2021","unstructured":"Luo M, Tan Y, Chen W, Hu B, Wang Z, Zhu D, Jiao H, Duan C, Zhu Y, Wang H (2021) Clinical efficacy of Temozolomide and its predictors in aggressive pituitary tumors and Pituitary Carcinomas: a systematic review and Meta-analysis. Front Neurol 12:700007","journal-title":"Front Neurol"},{"key":"1324_CR14","doi-asserted-by":"publisher","first-page":"916982","DOI":"10.3389\/fonc.2022.916982","volume":"12","author":"A Ishida","year":"2022","unstructured":"Ishida A, Shichi H, Fukuoka H, Shiramizu H, Inoshita N, Yamada S (2022) Temozolomide and Capecitabine Treatment for an aggressive Somatotroph Pituitary Tumor: a Case Report and Literature Review. Front Oncol 12:916982","journal-title":"Front Oncol"},{"key":"1324_CR15","doi-asserted-by":"publisher","first-page":"624686","DOI":"10.3389\/fendo.2021.624686","volume":"12","author":"T Nakano-Tateno","year":"2021","unstructured":"Nakano-Tateno T, Lau KJ, Wang J, McMahon C, Kawakami Y, Tateno T, Araki T (2021) Multimodal Non-Surgical treatments of aggressive pituitary tumors. Front Endocrinol 12:624686","journal-title":"Front Endocrinol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01324-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01324-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01324-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T09:24:26Z","timestamp":1688981066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01324-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01324-5","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"3 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MRG has received speaker fees from Recordati Rare Diseases, Ipsen, Novo Nordisk and Crinetics and is a member of the advisory board for Crinetics, Ipsen, Recordati Rare Disease and Novo Nordisk. LK has received speaker fees from Novartis and Ipsen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}